Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) – Purified

Anti-Mouse CD279 (PD-1) (Clone 29F.1A12) – Purified

Product No.: P383

[product_table name="All Top" skus="P383"]

- -
- -
Clone
29F.1A12
Target
PD-1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Programmed Death-1, CD279
Isotype
IgG2a κ
Applications
FC
,
IHC FF
,
PhenoCycler®
,
WB

- -
- -
Select Product Size

Data

- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Product Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 29F.1A12 recognizes an epitope on mouse PD-1.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Function
Lymphocyte clonal selection, peripheral tolerance
NCBI Gene Bank ID
Research Area
Cancer
.
Immunology
.
Inhibitory Molecules

References & Citations

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3.) Honjo, T. et al. (1992) EMBO J. 11:3887.
4.) Wurster S. et al. (2020) The Journal of Infectious Diseases 222(6):1989–994 Journal Link
5.) Lo, R. et al. (2021) Cancer Cell 39(10):1375-1387.e6 Journal Link
Flow Cytometry
IHC FF
PhenoCycler®
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.